48,860
edits
(→IHC) |
|||
Line 546: | Line 546: | ||
====Prostate carcinoma versus urothelial carcinoma==== | ====Prostate carcinoma versus urothelial carcinoma==== | ||
The ISUP panel recommends:<ref name=pmid25025364>{{cite journal |author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' |title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=1017–22 |year=2014 |month=August |pmid=25025364 |doi=10.1097/PAS.0000000000000254 |url=}}</ref> | |||
*PSA +ve (-ve in UCC). | |||
*GATA3 -ve (+ve in UCC). | |||
Another panel: | |||
*Prostate: PSA +ve, CK20 -ve, CK7 -ve. | *Prostate: PSA +ve, CK20 -ve, CK7 -ve. | ||
*Urothelial: CK20 +ve, CK7 +ve, PSA -ve. | *Urothelial: CK20 +ve, CK7 +ve, PSA -ve. |
edits